{
    "id": 32046,
    "fullName": "FGFR2 L617M",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FGFR2 L617M lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). L617M has been demonstrated to confer resistance to FGFR inhibitors as a secondary resistance mutation in the context of FGFR2 fusions (PMID: 31911531), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2020).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2263,
        "geneSymbol": "FGFR2",
        "terms": [
            "FGFR2",
            "BBDS",
            "BEK",
            "BFR-1",
            "CD332",
            "CEK3",
            "CFD1",
            "ECT1",
            "JWS",
            "K-SAM",
            "KGFR",
            "TK14",
            "TK25"
        ]
    },
    "variant": "L617M",
    "createDate": "01/14/2020",
    "updateDate": "01/14/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19851,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sapanisertib (MLN0128) therapy restored the sensitivity of transformed cells expressing both FGFR2-SHTN1 and FGFR2 E565A to treatment with Infigratinib (BGJ398), demonstrating synergistic effects (PMID: 31911531).",
            "molecularProfile": {
                "id": 34542,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A FGFR2 L617M"
            },
            "therapy": {
                "id": 9231,
                "therapyName": "BGJ398 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19816,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with cholangiocarcinoma harboring FGFR2-SHTN1 initially responded to treatment with Infigratinib (BGJ398), but progressed after eight months and via repeat tissue biopsy was found to have acquired FGFR2 E565A, and via circulating tumor DNA testing, FGFR2 L617M (PMID: 31911531).",
            "molecularProfile": {
                "id": 34542,
                "profileName": "FGFR2 - SHTN1 FGFR2 E565A FGFR2 L617M"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19843,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with AZD4547 in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19819,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with Infigratinib (BGJ398) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19857,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sapanisertib (MLN0128) therapy restored the sensitivity of transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M to treatment with AZD4547, demonstrating synergistic effects (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 9232,
                "therapyName": "AZD4547 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19848,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M were sensitive to treatment with Iclusig (ponatinib) in culture, demonstrating reduced cell viability (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19846,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with Balversa (erdafitinib) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19856,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sapanisertib (MLN0128) therapy restored the sensitivity of transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M to treatment with Balversa (erdafitinib), demonstrating synergistic effects (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 9233,
                "therapyName": "Erdafitinib + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19820,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with Infigratinib (BGJ398) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19845,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with Balversa (erdafitinib) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19858,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sapanisertib (MLN0128) therapy restored the sensitivity of transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M to treatment with Infigratinib (BGJ398), demonstrating synergistic effects (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 9231,
                "therapyName": "BGJ398 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19849,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 E565A were sensitive to treatment with Iclusig (ponatinib) in culture, demonstrating reduced cell viability (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19844,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with AZD4547 in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19847,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with Futibatinib (TAS-120) in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 1053,
                "therapyName": "Futibatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19855,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Iclusig (ponatinib) and Sapanisertib (MLN0128) resulted in synergistic effects in transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M in culture (PMID: 31911531).",
            "molecularProfile": {
                "id": 34543,
                "profileName": "FGFR2 - SHTN1 FGFR2 L617M"
            },
            "therapy": {
                "id": 9234,
                "therapyName": "Ponatinib + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17547,
                    "pubMedId": 31911531,
                    "title": "Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34525,
            "profileName": "FGFR2 L617M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34542,
            "profileName": "FGFR2 - SHTN1 FGFR2 E565A FGFR2 L617M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34543,
            "profileName": "FGFR2 - SHTN1 FGFR2 L617M",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}